Metraipolis › archive › dc_6dc1f98bf9dd
Benefit-risk profile of upadacitinib: exploratory post hoc analysis of phase 2b/3 studies in patients with moderately to severely active ulcerative colitis or… — Europe PMC PMID:41264726
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41264726
- DOI
- 10.1093/ecco-jcc/jjaf198
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-07T05:15:39.063Z
- SHA-256 of the archived text
15f1e6fb0d74d6ac5e164a83ede315209aadfbc3ed24600090c78755369d5b49- Stable URL of this page
https://metraipolis.com/documento/dc_6dc1f98bf9dd
How to cite
Benefit-risk profile of upadacitinib: exploratory post hoc analysis of phase 2b/3 studies in patients with moderately to severely active ulcerative colitis or… — Europe PMC PMID:41264726 — Europe PMC (en), https://europepmc.org/article/MED/41264726 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_6dc1f98bf9dd (Metraipolis archive dc_6dc1f98bf9dd, sha256 15f1e6fb0d74d6ac5e164a83ede315209aadfbc3ed24600090c78755369d5b49)
BibTeX
@misc{dc6dc1f98bf9dd,
title = {Benefit-risk profile of upadacitinib: exploratory post hoc analysis of phase 2b/3 studies in patients with moderately to severely active ulcerative colitis or… — Europe PMC PMID:41264726},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41264726},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_6dc1f98bf9dd; sha256 15f1e6fb0d74d6ac5e164a83ede315209aadfbc3ed24600090c78755369d5b49},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41264726. Agents can read the archived copy with the MCP tool read_document.